Switch to:
More From Other Websites
Hyperion Could Be Next Pharma Target With Orphan Drugs: Real M&A Mar 28 2015
The Pharmacyclics–AbbVie Merger: What Are the Details? Mar 28 2015
Neogen Lags Q3 Earnings & Revenue Estimates, Stock Down - Analyst Blog Mar 27 2015
Hospira Clinical Data Shows Proposed Biosimilar, Epoetin Hospira, Demonstrates Pharmacokinetic And... Mar 27 2015
Hospira Clinical Data Shows Proposed Biosimilar, Epoetin Hospira, Demonstrates Pharmacokinetic And... Mar 27 2015
9:00 am Hospira presents two studies that support an evaluation of biosimilarity of its proposed... Mar 27 2015
Biogen downgrade, Pfizer rises Mar 23 2015
AcelRx Starts Pivotal Study on Acute Pain Management Drug - Analyst Blog Mar 17 2015
The Zacks Analyst Blog Highlights: Novartis, Amgen, Hospira, Pfizer and Actavis - Press Releases Mar 10 2015
Merge's DR Systems Buyout Inspires Despite Q4 Revenue Lag - Analyst Blog Mar 09 2015
Hospira Statement on FDA Approval of the First Biosimilar in the United States Mar 06 2015
Inflectra™ (infliximab) patient registry reports interim results in the treatment of inflammatory... Mar 06 2015
Hospira Statement on FDA Approval of the First Biosimilar in the United States Mar 06 2015
Wednesday's Market Recap Mar 04 2015
HOSPIRA INC Files SEC form 8-K, Other Events Feb 27 2015
Increased Mergers and Acquistions Help, But Headwinds Persist Feb 27 2015
Biosimilar copies of blockbuster drug launch in major EU markets Feb 25 2015
Biosimilar copies of blockbuster drug launch in major EU markets Feb 25 2015
Pfizer Rapamune Under FDA Priority Review for Lung Disease - Analyst Blog Feb 23 2015
UPDATE - INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Investors of Hospira Inc. of Class Action... Feb 23 2015


Add Notes, Comments

If you want to ask a question, or report a bug, please create a support ticket.

User Comments

No comment yet


Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK